The global antibiotic resistance market size is estimated to reach USD 12.07 billion by 2025. According to a new report by Grand View Research, Inc., it is anticipated to post a CAGR of 5.6% during the forecast period. Rising burden of antibiotic-resistant infections and emergence of multi-drug resistant pathogens has been driving the market.
Biotech companies that are developing therapies for antibiotic-resistant infections include Melinta Therapeutics, Achaogen, and Nabriva Therapeutics. On the other hand, majority of large pharmaceutical companies don’t find this market lucrative enough due to slower growth in revenues for marketed drugs and lower return on investments. For instance, Novartis recently discontinued development of its antibacterial drugs for antibiotic resistance.
Manufacturers can obtain the Qualified Infectious Disease Product (QIDP) designation, which escalates the clinical review process for antibacterial therapies targeting high priority pathogens. The QIDP designation enables faster access to targeted agents and was introduced under the GAIN (Generating Antibiotic Incentives Now) Act, passed in 2012 as an extension to the U.S. FDA Safety and Innovation Act. The legislation aims to encourage the development of novel therapies for growing burden and severity of infections with antibiotic resistance.
To request a sample copy or view summary of this report, click the link below:
Further key findings from the report suggest:
In 2017, the market by cUTI disease registered significant sales due to elevated rate of resistance in extended-spectrum beta-lactamase (ESBL)-producing and carbapenem-resistant Enterobacteriaceae and P. aeruginosa strains
The combination therapies segment, which includes fixed-dose combinations of beta lactams and beta lactamase inhibitors, is projected to witness the fastest growth rate over the forecast period
Infections due to E. coli pathogens that are ESBL-producing and carbapenem-resistant led in terms of sales revenue in 2017 due to high treatment cost
On the geographical front, North America was the dominant revenue contributor in the market in 2017. Improving reimbursement scenario with new technology add-on payment provision is promoting the use of novel products in this region
Among pharmaceutical companies, Merck, Allergan, and Pfizer were the key players with top-selling drugs in the antibiotic resistance market in 2017.
Grand View Research has segmented the global antibiotic resistance market on the basis of disease, pathogen type, drug class, and region:
Antibiotic Resistance Disease Outlook (Revenue, USD Billion, 2014 - 2025)
Complicated Urinary Tract Infection (cUTI)
Complicated Intra-Abdominal Infections (cIAI)
Blood Stream Infections (BSI)
Clostridium difficile infections (CDI)
Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
Community Acquired Bacterial Pneumonia (CABP)
Antibiotic Resistance Pathogen Outlook (Revenue, USD Billion, 2014 - 2025)
Acinetobacter baumannii (Carbapenem-Resistant)
Pseudomonas aeruginosa (Carbapenem-Resistant)
E. coli/K. pneumoniae (Carbapenem-Resistant)
Streptococcus pneumoniae (Penicillin-Non-Susceptible)
Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
Enterococcus faecium (Vancomycin-Resistant)
Haemophilus Influenzae (Ampicillin-Resistant)
Antibiotic Resistance Drug Class Outlook (Revenue, USD Billion, 2014 - 2025)
Antibiotic Resistance Regional Outlook (Revenue, USD Billion, 2014 - 2025)
Middle East and Africa
This report has a service guarantee. We stand by our report quality.
Your transaction & personal information is safe and secure.
Design an exclusive study to serve your research needs.
Get your queries resolved from an industry expert.
Avail customized purchase options to meet your research needs:
"The quality of research they have done for us has been excellent..."